Device Trial Radar · NCT07629206
Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jul 17, 2026
Primary completion
Jul 2034
Study completion Sep 2034
Sponsor
- Lead sponsor
- IceCure Medical Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The FDA has granted marketing authorization for the ProSense® Cryoablation System for the local treatment of patients aged 70 years or older with low-risk early-stage breast cancer who are also receiving adjuvant hormone therapy. This clinical trial is designed to collect additional data on the safety and effectiveness of cryoablation when used as part of routine clinical care. Specifically, the study will evaluate recurrence rates following the procedure for up to 5 years post-treatment. In addition, linkage to claims data will be used to assess long-term outcomes, including breast cancer-related surgeries, mammograms and other breast imaging procedures, breast biopsies, and all-cause mortality.
Conditions
- Low-Risk, Early Stage Breast Cancer
Interventions
CryoablationDevice
Cryoablation procedure, without resection, using the IceCure Medical ProSense® Cryoablation System. Patients will be also provided with adjuvant endocrine therapy for 5 years post-treatment. The IceCure ProSense® cryoablation system is intended for cryogenic destruction of tissue by the application of extreme cold temperatures.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Ipsilateral Breast Tumor Recurrence (IBTR) RateTime frame: 5 Years
- Confirmed and suspected Ipsilateral Breast Tumor Recurrence (IBTR) RateTime frame: 5 Years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Glendale, California · Recruiting
Legacy Medical Group-Surgical Oncology at Good Samaritan
Portland, Oregon · Recruiting
The West Clinic, PC dba West Cancer Center
Germantown, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.